Download PDF
Exp Clin Endocrinol Diabetes 2003; 111(5): 246-250
DOI: 10.1055/s-2003-41284
Review

J. A. Barth Verlag in Georg Thieme Verlag Stuttgart · New York

Influence of Plasma Free Fatty Acids on Lipoprotein Synthesis and Diabetic Dyslipidemia

U. Julius 1
  • 1Medical Clinic and Outpatient Department III, University Hospital at the University of Technology, Dresden, Germany
Further Information

Publication History

Received: July 17, 2002 First decision: November 24, 2002

Accepted: March 3, 2003

Publication Date:
02 September 2003 (online)

Also available at
    Permissions and Reprints

Abstract

The regulation of hepatic VLDL secretion mainly depends on apolipoprotein (apo) B synthesis, on microsomal triglyceride transfer protein, insulin and the availability of triglycerides, free fatty acids (FFA) and cholesteryl ester. Four sources of fatty acids are used for lipoprotein synthesis: de-novo lipogenesis, cytoplasmic triglyceride stores, fatty acids derived from lipoproteins taken up directly by the liver and plasma FFA. Quantitatively, de-novo lipogenesis plays a minor role in regulating VLDL synthesis, but evidently it is elevated under conditions of high carbohydrate feeding. Cytoplasmic triglyceride stores appear to essentially contribute to VLDL triglycerides. Plasma FFA enter the hepatocytes and are either oxidized or esterified. The relationship between oxidation and esterification appears to be important in regulating the VLDL synthesis. An enhanced esterification is accompanied by increased VLDL secretion. The addition of oleic acid to hepatocytes has been shown to stimulate production of VLDL triglyceride and apoB. In human beings, an acute experimental elevation of plasma FFA stimulates VLDL production. In healthy men strong positive relations were found between the late increases in large triglyceride-rich lipoproteins and plasma FFA concentrations after 6 h following a mixed meal. In contrast, n-3 fatty acids impair VLDL assembly and secretion.

Chronic hyperinsulinemia seems to stimulate VLDL production. On the other hand, the short-term addition of insulin has been shown to inhibit VLDL-triglyceride and apoB production in vitro. There is in vivo evidence that acute hyperinsulinemia suppresses VLDL-apoB and VLDL-triglyceride production in insulin-sensitive humans. Part of this action is due to suppression of plasma FFA. In patients with impaired glucose tolerance (IGT), VLDL production was increased when compared with subjects with normal glucose (NGT). When infusing a lipid emulsion, VLDL production could not be further stimulated in IGT patients in contrast to NGT persons. Hypertriglyceridemia in type 2 diabetes mellitus is usually the consequence of a VLDL overproduction. In type 2 diabetic patients, in contrast to normal men, insulin failed to suppress VLDL1 particle release. In normal men, an elevation of blood glucose led to a decrease in fatty acid oxidation and an increase in hepatic triglyceride secretion. Under these conditions, ∼ 30 % of total VLDL triglycerides coming out of the liver did not originate from plasma FFA. In conclusion, plasma FFA seem to play an important role in stimulating hepatic VLDL production. Other factors such as chronic hyperinsulinemia or nutrition modify this effect.

Key words

Free fatty acids - hepatic VLDL secretion - insulin - insulin resistance - diabetic dyslipidemia

References

  • 1 Aarsland A, Wolfe R R. Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men.  J Lipid Res. 1998;  39 1280-1286
    PubMedGoogle Scholar
  • 2 Adeli K, Taghibiglou C, Van Iderstine S C, Lewis G F. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance.  Trends Cardiovasc Med. 2001;  11 170-176
    CrossrefPubMedGoogle Scholar
  • 3 Boquist S, Hamsten A, Karpe F, Ruotolo G. Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of postprandial triglyceride-rich lipoproteins in healthy middle-aged men.  Diabetologia. 2000;  43 185-193
    CrossrefPubMedGoogle Scholar
  • 4 Bordin P, Bodamer O A, Venkatesan S, Gray R M, Bannister P A, Halliday D. Effects of fish oil supplementation on apolipoprotein B100 production and lipoprotein metabolism in normolipidaemic males.  Eur J Clin Nutr. 1998;  52 104-109
    CrossrefPubMedGoogle Scholar
  • 5 Bremer J. The biochemistry of hypo- and hyperlipidemic fatty acid derivatives: metabolism and metabolic effects.  Prog Lipid Res. 2001;  40 231-268
    PubMedGoogle Scholar
  • 6 Brown A M, Castle J, Hebbachi A M, Gibbons G F. Administration of n-3 fatty acids in the diets of rats or directly to hepatocyte cultures results in different effects on hepatocellular ApoB metabolism and secretion.  Arterioscler Thromb Vasc Biol. 1999;  19 106-114
    PubMedGoogle Scholar
  • 7 Cummings M H, Watts G F, Umpleby A M, Hennessy T R, Naoumova R, Slavin B M, Thompson G R, Sönksen P H. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM.  Diabetologia. 1995;  38 959-967
    CrossrefPubMedGoogle Scholar
  • 8 Dashti N, Feng Q, Franklin F A. Long-term effects of cis and trans monounsaturated (18: 1) and saturated (16: 0) fatty acids on the synthesis and secretion of apolipoprotein A-I- and apolipoprotein B-containing lipoproteins in HepG2 cells.  J Lipid Res. 2000;  41 1980-1990
    PubMedGoogle Scholar
  • 9 Goldberg I J. Clinical review 124: Diabetic dyslipidemia: causes and consequences.  J Clin Endocrinol Metab. 2001;  86 965-971
    CrossrefPubMedGoogle Scholar
  • 10 Hellerstein M K, Christiansen M, Kaempfer S, Kletke C, Wu K, Reid J S, Mulligan K, Hellerstein N S, Shackleton C H. Measurement of de novo hepatic lipogenesis in humans using stable isotopes.  J Clin Invest. 1991;  87 1841-1852
    PubMedGoogle Scholar
  • 11 Julius U, Leonhardt W, Schulze J, Schollberg K, Haller H. Insulin resistance in diabetics and non-diabetics with impaired triglyceride removal.  Exp Clin Endocrinol. 1984;  83 225-230
    PubMedGoogle Scholar
  • 12 Lang C A, Davis R A. Fish oil fatty acids impair VLDL assembly and/or secretion by cultured rat hepatocytes.  J Lipid Res. 1990;  31 2079-2086
    PubMedGoogle Scholar
  • 13 Laws A. Free fatty acids, insulin resistance and lipoprotein metabolism.  Curr Opin Lipidol. 1996;  7 172-177
    PubMedGoogle Scholar
  • 14 Lewis G F. Fatty acid regulation of very low density lipoprotein production.  Curr Opin Lipidol. 1997;  8 146-153
    PubMedGoogle Scholar
  • 15 Lewis G F, Uffelman K D, Szeto L W, Steiner G. Effects of acute hyperinsulinemia on VLDL triglyceride and VLDL apoB production in normal weight and obese individuals.  Diabetes. 1993;  42 833-842
    CrossrefPubMedGoogle Scholar
  • 16 Lewis G F, Zinman B, Uffelman K D, Szeto L, Weller B, Steiner G. VLDL production is decreased to a similar extent by acute portal vs. peripheral venous insulin.  Am J Physiol. 1994;  267 E566-572
    PubMedGoogle Scholar
  • 17 Lewis G F, Uffelman K D, Szeto L W, Weller B, Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.  J Clin Invest. 1995;  95 158-166
    CrossrefPubMedGoogle Scholar
  • 18 Lin Y, Schuurbiers E, Van der Veen S, De Deckere E A. Conjugated linoleic acid isomers have differential effects on triglyceride secretion in Hep G2 cells.  Biochim Biophys Acta. 2001;  1533 38-46
    PubMedGoogle Scholar
  • 19 Malmstrom R, Packard C J, Caslake M, Bedford D, Stewart P, Yki-Jarvinen H, Shepherd J, Taskinen M R. Defective regulation of triglyceride metabolism by insulin in the liver in NIDDM.  Diabetologia. 1997;  40 454-462
    CrossrefPubMedGoogle Scholar
  • 20 Malmstrom R, Packard C J, Caslake M, Bedford D, Stewart P, Shepherd J, Taskinen M R. Effect of heparin-stimulated plasma lipolytic activity on VLDL APO B subclass metabolism in normal subjects.  Atherosclerosis. 1999;  146 381-390
    CrossrefPubMedGoogle Scholar
  • 21 Mittendorfer B, Sidossis L S. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short-term, high-carbohydrate diets.  Am J Clin Nutr. 2001;  73 892-899
    PubMedGoogle Scholar
  • 22 Mostaza J M, Vega G L, Snell P, Grundy S M. Abnormal metabolism of free fatty acids in hypertriglyceridaemic men: apparent insulin resistance of adipose tissue.  J Intern Med. 1998;  243 265-274
    CrossrefPubMedGoogle Scholar
  • 23 Parks E J, Krauss R M, Christiansen M P, Neese R A, Hellerstein M K. Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride assembly, production, and clearance.  J Clin Invest. 1999;  104 1087-1096
    PubMedGoogle Scholar
  • 24 Pietzsch J, Julius U, Kirch C, Fischer S, Hanefeld M. Very low density lipoprotein overproduction is maximally expressed in early insulin resistant states.  Ann NY Acad Sci. 1999;  892 319-322
    PubMedGoogle Scholar
  • 25 Sidossis L S, Mittendorfer B, Walser E, Chinkes D, Wolfe R R. Hyperglycemia-induced inhibition of splanchnic fatty acid oxidation increases hepatic triacylglycerol secretion.  Am J Physiol. 1998;  275 E798-805
    PubMedGoogle Scholar
  • 26 Sniderman A D, Scantlebury T, Cianflone K. Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus.  Ann Intern Med. 2001;  135 447-459
    PubMedGoogle Scholar
  • 27 Steiner G, Lewis G F. Hyperinsulinemia and triglyceride-rich lipoproteins.  Diabetes. 1996;  45 (Suppl 3) S24-S26
    PubMedGoogle Scholar
  • 28 Taskinen M R. Pathogenesis of dyslipidemia in type 2 diabetes.  Exp Clin Endocrinol Diabetes. 2001;  109 (Suppl 2) S180-S188
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Wiggins D, Gibbons G F. Origin of hepatic very-low-density lipoprotein triacylglycerol: the contribution of cellular phospholipid.  Biochem J. 1996;  320 673-679
    PubMedGoogle Scholar
  • 30 Zheng X, Avella M, Botham K M. Comparison of the effects of dietary n-3 and n-6 polyunsaturated fatty acids on very-low-density lipoprotein secretion when delivered to hepatocytes in chylomicron remnants.  Biochem J. 2001;  357 481-487
    CrossrefPubMedGoogle Scholar

Prof. Dr. Ulrich Julius

Medizinische Klinik und Poliklinik III
Universitätsklinikum Carl Gustav Carus

Fetscherstraße 74

01307 Dresden

Germany

Phone: + 493514582306

Fax: + 49 35 14 58 53 06

Email: julius@rcs.urz.tu-dresden.de